Compare INSE & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSE | TNXP |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.2M | 198.6M |
| IPO Year | 2014 | 2008 |
| Metric | INSE | TNXP |
|---|---|---|
| Price | $8.18 | $11.46 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 91.2K | ★ 441.7K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $199,800,000.00 | $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | $4.26 | $38.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.25 | 29.85 |
| 52 Week Low | $6.11 | $10.87 |
| 52 Week High | $9.95 | $69.65 |
| Indicator | INSE | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 62.74 | 42.21 |
| Support Level | $7.91 | N/A |
| Resistance Level | $8.36 | $14.85 |
| Average True Range (ATR) | 0.40 | 0.84 |
| MACD | 0.05 | -0.16 |
| Stochastic Oscillator | 97.82 | 19.82 |
Inspired Entertainment Inc is a gaming technology company, supplying content, platform and other products and services to licensed online and land-based lottery, betting and gaming operators of various countries through a range of distribution channels, on a business-to-business basis. The company provides digital gaming solutions (i) on its own proprietary and secure network, which accommodates a wide range of devices, including land-based gaming machine terminals, mobile devices and online computer applications, and (ii) through third party networks. It operates in four business segments: Gaming, Virtual Sports, Interactive and Leisure. The majority of revenue is derived from the Leisure Segment, which includes the supply of the gaming and amusement machines.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.